Repligen Corporation (RGEN)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $10.73B
Last updated: Nov 17, 2026 at 11:06 AM ET
Repligen Corporation (RGEN) Financials: Revenue, Profit and Cash Flow
Repligen reported revenue of $738.26M for the fiscal year ended Dec 31, 2025, up 16.4% from the year before. That year, net income was $48.89M with a net margin of 6.6%, operating cash flow was $117.42M and free cash flow was $93.90M. The quarter ended Sep 30, 2026 had revenue of $209.31M and net income of -$38.43M.
Revenue and Margins
The operating margin was 7.5% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $208.98M, a compound annual rate of 15.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $738.26M | +16.4% | 52.3% | 7.5% | 6.6% |
| Dec 2024 | $634.44M | +0.3% | 43.3% | -5.5% | -4.0% |
| Dec 2023 | $632.36M | -21.1% | 44.0% | 7.5% | 5.6% |
| Dec 2022 | $801.54M | +19.5% | 56.9% | 28.0% | 23.2% |
| Dec 2021 | $670.53M | +83.1% | 58.3% | 24.9% | 19.1% |
| Dec 2020 | $366.26M | +35.5% | 57.2% | 19.1% | 16.4% |
| Dec 2019 | $270.25M | +39.3% | 55.9% | 13.4% | 7.9% |
| Dec 2018 | $194.03M | +37.4% | 55.4% | 13.4% | 8.6% |
| Dec 2017 | $141.24M | -32.4% | 52.5% | 9.9% | 20.1% |
| Dec 2016 | $208.98M | N/A | 77.5% | 7.6% | 5.6% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $738.26M | $634.44M | $632.36M | $801.54M | $670.53M | $366.26M | $270.25M | $194.03M | $141.24M | $208.98M |
| Cost of revenue | $352.01M | $359.79M | $353.92M | $345.83M | $279.28M | $156.63M | $119.10M | $86.53M | $67.05M | $47.12M |
| Gross profit | $386.25M | $274.64M | $278.44M | $455.71M | $391.25M | $209.63M | $151.15M | $107.50M | $74.19M | $161.87M |
| Research and development | $54.18M | $43.20M | $42.72M | $43.94M | $34.27M | $20.18M | $19.45M | $15.82M | $8.67M | $7.36M |
| Operating income | $55.17M | -$35.11M | $47.70M | $224.67M | $167.25M | $69.82M | $36.08M | $25.99M | $14.01M | $15.97M |
| Net income | $48.89M | -$25.51M | $35.60M | $185.96M | $128.29M | $59.93M | $21.41M | $16.62M | $28.35M | $11.68M |
| EBITDA | $151.71M | $43.13M | $118.75M | $266.12M | $225.18M | $106.28M | $64.17M | $46.28M | $27.80M | $22.72M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $209.31M | $204.13M | $194.25M | $197.91M | $188.81M | $182.37M | $169.17M | $167.55M | $154.87M | $158.84M | $153.18M | $166.62M |
| Gross profit | $110.99M | $110.04M | $108.28M | $103.83M | $100.52M | $93.00M | $91.37M | $38.84M | $77.49M | $81.53M | $76.79M | $78.48M |
| Operating income | -$29.55M | $13.98M | $15.94M | $17.87M | $16.82M | $13.90M | $6.58M | -$36.50M | -$7.83M | $5.47M | $3.75M | $9.87M |
| Net income | -$38.43M | $5.01M | $8.33M | $13.29M | $14.91M | $14.87M | $5.83M | -$33.87M | -$654.00K | $5.71M | $3.30M | -$16.45M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $547.26M by $18.76M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.95B | $2.83B | $2.83B | $2.53B | $2.36B | $1.90B | $1.40B | $774.62M | $743.52M | $288.91M |
| Current assets | $1.14B | $1.07B | $1.11B | $998.12M | $931.68M | $902.38M | $641.83M | $275.74M | $242.78M | $184.15M |
| Cash and equivalents | $566.02M | $757.36M | $751.32M | $523.46M | $603.81M | $717.29M | $528.39M | $193.82M | $173.76M | $122.23M |
| Total liabilities | $843.57M | $856.95M | $866.34M | $620.90M | $608.29M | $373.74M | $340.35M | $159.05M | $151.97M | $120.15M |
| Short-term debt | $5.05M | $17.13M | $82.44M | $298.56M | $255.26M | $243.74M | $0 | $103.49M | $0 | $95.27M |
| Long-term debt | $542.21M | $525.57M | $510.14M | $0 | N/A | N/A | $232.77M | N/A | $99.25M | $95.27M |
| Shareholder equity | $2.11B | $1.97B | $1.96B | $1.91B | $1.75B | $1.53B | $1.06B | $615.57M | $591.55M | $168.76M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.93B | $2.95B | $2.93B | $2.95B | $2.92B | $2.90B | $2.85B | $2.83B | $2.83B | $2.87B | $2.85B | $2.83B |
| Total liabilities | $834.67M | $838.15M | $825.31M | $843.57M | $840.62M | $839.89M | $866.66M | $856.95M | $813.96M | $881.57M | $888.10M | $866.34M |
| Cash and equivalents | $726.96M | $606.78M | $582.65M | $566.02M | $748.75M | $708.86M | $697.23M | $757.36M | $783.96M | $809.15M | $780.62M | $751.32M |
| Shareholder equity | $2.09B | $2.11B | $2.11B | $2.11B | $2.08B | $2.06B | $1.99B | $1.97B | $2.02B | $1.98B | $1.97B | $1.96B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 80.0% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $117.42M | $175.39M | $113.92M | $172.08M | $119.02M | $62.63M | $67.22M | $32.77M | $17.45M | $7.52M |
| Capital expenditures | $23.52M | $25.68M | $36.22M | $84.83M | $67.09M | $22.45M | $18.50M | $11.89M | $5.45M | $4.33M |
| Free cash flow | $93.90M | $149.72M | $77.70M | $87.25M | $51.93M | $40.17M | $48.71M | $20.88M | $12.00M | $3.20M |
| Dividends paid | N/A | N/A | $565.68M | $17.02M | $2.90M | N/A | $490.00K | N/A | $0 | $798.00K |
| Share repurchases | $0 | $0 | $14.39M | $0 | $0 | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$298.47M | -$86.38M | -$123.28M | -$233.24M | -$221.17M | -$201.38M | -$205.31M | -$14.04M | -$98.70M | -$49.19M |
| Financing cash flow | -$15.21M | -$82.90M | $248.96M | -$13.34M | $961.00K | $305.92M | $484.87M | $3.41M | $129.94M | $112.11M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $43.10M | $32.77M | $28.30M | $25.70M | $48.10M | $28.61M | $15.01M | $39.18M | $49.32M | $42.19M | $44.71M | $29.07M |
| Capital expenditures | $4.95M | $5.33M | $4.71M | $8.15M | $4.70M | $7.10M | $3.56M | $5.54M | $6.98M | $4.81M | $8.35M | $11.09M |
| Free cash flow | $38.15M | $27.43M | $23.59M | $17.55M | $43.40M | $21.51M | $11.44M | $33.64M | $42.34M | $37.38M | $36.36M | $17.98M |
Frequently Asked Questions About RGEN
What is Repligen's annual revenue?
Repligen reported revenue of $738.26M for the fiscal year ended Dec 31, 2025.
How fast is Repligen's revenue growing?
Revenue was up 16.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -2.7%.
Is Repligen profitable?
Yes. Repligen reported net income of $48.89M for the fiscal year ended Dec 31, 2025, with a net margin of 6.6%.
How much free cash flow does RGEN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $117.42M minus capital expenditures of $23.52M produced free cash flow of $93.90M.
How much debt does Repligen have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $542.21M, short-term debt of $5.05M and cash and equivalents of $566.02M.
RGEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts